Research map: Early and High‐Dose Glucocorticoid Use and Survival in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Multicenter Target Trial Emulation

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions · 2026 · Related
  3. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies · Erik B von Elm · 2014 · 10249 citations · Cited by this paper
  4. Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure · 2026 · Related
  5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline · Julie Renee Brahmer · 2018 · 3767 citations · Cited by this paper
  6. ASCPT News · 2026 · Related
  7. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. · Miguel Ángel Hernán · 2016 · 3061 citations · Cited by this paper
  8. Reframing the Landscape for Achieving Equitable Pharmacotherapy Health Outcomes: Introducing Pharmacogenequity · 2026 · Related
  9. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  10. The Multiple Criteria Qualitative Value‐Based Pricing Framework “ MARIE ” for Novel Cell and Gene Therapy · 2026 · Related
  11. Immortal Time Bias in Pharmacoepidemiology · Samy Suissa · 2007 · 1793 citations · Cited by this paper
  12. In This Issue · 2026 · Related
  13. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial · Naiyer A. Rizvi · 2015 · 1437 citations · Cited by this paper
  14. From Non‐Cancer Pain to Cancer Survivorship: Applying Opioid Deprescribing Lessons across the Divide · 2026 · Related
  15. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer · Kathryn Cecilia Arbour · 2018 · 1088 citations · Cited by this paper
  16. Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study · 2026 · Related
  17. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy · Amber Jin Giles · 2018 · 501 citations · Cited by this paper
  18. Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2 / MATE ‐Mediated Renal Drug‐Drug Interactions in Healthy Volunteers · 2026 · Related
  19. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up · John B.A.G. Haanen · 2018 · 435 citations · Cited by this paper
  20. Statins Safety Signals: From Precautions to Proportionate Evidence‐Based Labeling · 2026 · Related
  21. Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications · Biagio Ricciuti · 2019 · 334 citations · Cited by this paper
  22. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice · Alessio Cortellini · 2020 · 276 citations · Cited by this paper
  23. Propensity Score Matching with Time‐Dependent Covariates · Bo Lü · 2005 · 253 citations · Cited by this paper
  24. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors · Giovanni Fucà · 2019 · 216 citations · Cited by this paper
  25. Time‐related biases in pharmacoepidemiology · Samy Suissa · 2020 · 176 citations · Cited by this paper
  26. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors · Sarah Cook · 2024 · 172 citations · Cited by this paper
  27. Sensitivity Analysis for Unmeasured Confounding in Meta-Analyses · Maya B. Mathur · 2019 · 157 citations · Cited by this paper
  28. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy · Alessio Cortellini · 2021 · 152 citations · Cited by this paper
  29. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes · Lorella Lanza · 1996 · 112 citations · Cited by this paper
  30. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer · Diana Vesselinovitch Maslov · 2021 · 103 citations · Cited by this paper
  31. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events · Marie Kostine · 2021 · 101 citations · Cited by this paper
  32. Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer · Martin Svatoň · 2020 · 90 citations · Cited by this paper
  33. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era · Laura Kalfeist · 2022 · 80 citations · Cited by this paper
  34. DAG Program: · Sven Knüppel · 2009 · 76 citations · Cited by this paper
  35. Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells · Christian S. Hinrichs · 2005 · 75 citations · Cited by this paper
  36. Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab · Coraline Duménil · 2018 · 60 citations · Cited by this paper
  37. Clinical Trial Emulation by Matching Time-dependent Propensity Scores · Rémi Lenain · 2020 · 44 citations · Cited by this paper
  38. Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation · Louis Gaucher · 2021 · 37 citations · Cited by this paper
  39. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy · Giannis Mountzios · 2020 · 33 citations · Cited by this paper

Source: OpenAlex (CC0)